First-in-human study evaluates Strand’s ability to unlock the potential of systemic mRNA-encoded medicines with an IL-12 ...
Adjuvia Therapeutics, a biotechnology company developing novel therapeutics to treat mitochondrial dysfunction and disease, ...
Grant for $15 million will create new access to critical inpatient mental health services for children and teens across ...
BARDA awards IAVI US $36 million of a contract valued up to US $99 million to advance development, manufacturing, and ...
If you’re interested in working at a biopharma in New York, check out the open roles at these eight companies. Regeneron has ...
As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming ...
About pridopidine Pridopidine is an investigational highly selective, oral sigma-1 receptor (S1R) agonist. S1R has been shown to play a role in stimulating multiple neuroprotective pathways impaired ...
In tandem, Blue Arbor will also begin development of the RESTORE™ ISU. “Blue Arbor’s technology has the potential to set a new standard in prosthetic control,” said Oliver Jakobi, Chief Executive ...
Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
Lead FDA-track program targets a serious pediatric disease with no FDA-approved treatment and could qualify for a ...
Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over ...
The FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results